Ascendis Pharma A/S (ASND) traded higher as the market focused on two near-term calendar catalysts: a scheduled first-quarter 2026 earnings release and business update on May 7 before the U.S. open, and the final day for holders to convert the company’s 2.25% convertible senior notes due 2028 ahead of an announced redemption. The conversion option, which remains available until 5:00 p.m. New York time on May 4, creates a near-term technical and positioning dynamic as investors handicap potential share issuance versus a clean cash redemption.

Ascendis previously called all $575.0 million principal amount of its 2.25% convertible notes due 2028 for redemption on May 6, 2026, at 100% of principal plus accrued interest. The company disclosed that up to about 3.64 million ordinary shares could be issued if all notes are converted during the make-whole conversion period that runs through May 4, 2026, highlighting a key swing factor for short-term supply/dilution expectations and post-redemption capital structure.

The May 7 update is the next fundamental checkpoint, with investors likely focused on commercial execution and 2026 milestones following recent pipeline and launch-related updates in 2026. Near term, trading may remain sensitive to any signals on how many noteholders elect conversion versus cash, and whether the redemption materially reduces future interest expense and improves financial flexibility going into the second half of 2026.